Hepatitis B
Conditions
Keywords
Engerix-B, Hepatitis B
Brief summary
This study will evaluate the immune response of healthy subjects who received neonatal vaccination course with GSK Biologicals' Engerix™-B vaccine, approximately 20 years ago. The presence of immune memory against hepatitis B surface antigen (HBsAg) in these subjects will be investigated by the administration of a challenge dose of hepatitis B vaccine and the comparison of their antibody concentration before and one month after vaccination. This protocol posting deals with objectives & outcome measures of the booster phase. No new subjects will be recruited during this booster phase of the study.
Interventions
BIOLOGICALEngerixTM-B
Intramuscular injection, one dose.
Sponsors
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 22 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female who received the complete neonatal primary vaccination course of Engerix™-B in the 103860/273 primary study approximately 20 years earlier. * Anti-HBs antibody concentrations less than the specified value at the last available follow-up time-point. * Written informed consent obtained from the subject. * Healthy subjects as established by medical history and clinical examination before entering into the study. * If the subject is female, she must be of non-childbearing potential,or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination.
Exclusion criteria
* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the Engerix™-B challenge dose, or planned use during the study period. * Chronic administration (defined as more than 14 days) of immunosuppressant or other immune-modifying drugs within six months prior to challenge dose administration. * Planned administration/ administration of a vaccine not foreseen by the study protocol starting from 30 days before the challenge dose and ending 30 days after. * Administration of a hepatitis B vaccine outside the context of this study between the follow-up time-point at which anti-HBs antibody concentrations was less than the specified value and the current challenge dose study visit. * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * Acute disease at the time of enrolment. * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection. * Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. * Administration of immunoglobulins and/or any blood products within the three months preceding the challenge dose visit or planned administration during the study period. * Pregnant or lactating female. * Female planning to become pregnant or planning to discontinue contraceptive precautions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects With an Anamnestic Response to a Challenge Dose of Hepatitis B Virus (HBV) Vaccine as Measured by Enzyme-Linked Immunosorbent Assay (ELISA). | One month after the hepatitis B vaccine challenge dose. | Anamnestic response to the challenge dose is defined as: - At least (i.e. greater than or equal to) a 4-fold rise in post-challenge anti-HBsAg antibody concentrations in subjects seropositive at the last available follow-up time-point. -Post-challenge dose anti-HBsAg antibody concentrations \>= 10 mIU/mL in subjects seronegative at the last available follow-up time-point. |
| Number of Subjects With an Anamnestic Response to a Challenge Dose of Hepatitis B Virus (HBV) Vaccine as Measured by ChemiLuminescence ImmunoAssay (CLIA). | One month after the hepatitis B vaccine challenge dose. | Anamnestic response to the challenge dose is defined as: - At least (i.e. greater than or equal to) a 4-fold rise in post-challenge anti-HBsAg antibody concentrations in subjects seropositive at the last available follow-up time-point. -Post-challenge dose anti-HBsAg antibody concentrations \>= 10 mIU/mL in subjects seronegative at the last available follow-up time-point. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by ELISA. | One month after the hepatitis B vaccine challenge dose. | Concentrations given as GMC expressed as milli-international unit per millilitre (mIU/mL). |
| Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by CLIA. | One month after the hepatitis B vaccine challenge dose. | Concentrations given as GMC expressed as milli-international unit per millilitre (mIU/mL). |
| Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by ELISA. | One month after the hepatitis B vaccine challenge dose. | Cut-off values assessed were as follows: ≥3.3 milli-international units/milliliter (mIU/mL), ≥10 mIU/mL, ≥100 mIU/mL |
| Number of Subjects That Experienced Serious Adverse Events (SAEs) | During the entire study period after the challenge dose (1 month). | SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. |
| Number of Subjects Experiencing Any, Grade 3 and Related to Vaccination Unsolicited Symptoms. | During the 31-day follow-up period after the hepatitis B vaccine challenge dose. | Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 symptom is any event that prevented normal activities. Related symptom is an event that was considered by investigator as causally related to the study vaccination. |
| Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by CLIA. | One month after the hepatitis B vaccine challenge dose. | Cut-off values assessed were as follows: ≥6.2 milli-international units/milliliter (mIU/mL), ≥10 mIU/mL, ≥100 mIU/mL |
Countries
Thailand
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study. | 9 |
| Engerix(3-dose)+HBIg Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study. | 16 |
| Engerix(4-dose) Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study. | 8 |
| Engerix(3-dose) Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study. | 16 |
| Total | 49 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Protocol Violation | 0 | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) | Engerix(3-dose)+HBIg | Engerix(4-dose) | Engerix(3-dose) | Total |
|---|---|---|---|---|---|
| Age, Continuous | 19.3 Years STANDARD_DEVIATION 0.5 | 19.6 Years STANDARD_DEVIATION 0.5 | 19.8 Years STANDARD_DEVIATION 0.46 | 19.5 Years STANDARD_DEVIATION 0.52 | 19.5 Years STANDARD_DEVIATION 0.51 |
| Sex: Female, Male Female | 6 Participants | 6 Participants | 2 Participants | 7 Participants | 21 Participants |
| Sex: Female, Male Male | 3 Participants | 10 Participants | 6 Participants | 9 Participants | 28 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 1 / 9 | 0 / 16 | 0 / 8 | 0 / 16 |
| serious Total, serious adverse events | 0 / 9 | 0 / 16 | 0 / 8 | 0 / 16 |
Outcome results
Primary
Number of Subjects With an Anamnestic Response to a Challenge Dose of Hepatitis B Virus (HBV) Vaccine as Measured by ChemiLuminescence ImmunoAssay (CLIA).
Anamnestic response to the challenge dose is defined as: - At least (i.e. greater than or equal to) a 4-fold rise in post-challenge anti-HBsAg antibody concentrations in subjects seropositive at the last available follow-up time-point. -Post-challenge dose anti-HBsAg antibody concentrations \>= 10 mIU/mL in subjects seronegative at the last available follow-up time-point.
Time frame: One month after the hepatitis B vaccine challenge dose.
Population: Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects who had received the challenge dose of HBV vaccine and for whom data concerning immunogenicity measures were available at the post-HBV vaccine challenge dose time point.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) | Number of Subjects With an Anamnestic Response to a Challenge Dose of Hepatitis B Virus (HBV) Vaccine as Measured by ChemiLuminescence ImmunoAssay (CLIA). | 7 Subjects |
| Engerix(3-dose)+HBIg | Number of Subjects With an Anamnestic Response to a Challenge Dose of Hepatitis B Virus (HBV) Vaccine as Measured by ChemiLuminescence ImmunoAssay (CLIA). | 11 Subjects |
| Engerix(4-dose) | Number of Subjects With an Anamnestic Response to a Challenge Dose of Hepatitis B Virus (HBV) Vaccine as Measured by ChemiLuminescence ImmunoAssay (CLIA). | 5 Subjects |
| Engerix(3-dose) | Number of Subjects With an Anamnestic Response to a Challenge Dose of Hepatitis B Virus (HBV) Vaccine as Measured by ChemiLuminescence ImmunoAssay (CLIA). | 12 Subjects |
Primary
Number of Subjects With an Anamnestic Response to a Challenge Dose of Hepatitis B Virus (HBV) Vaccine as Measured by Enzyme-Linked Immunosorbent Assay (ELISA).
Anamnestic response to the challenge dose is defined as: - At least (i.e. greater than or equal to) a 4-fold rise in post-challenge anti-HBsAg antibody concentrations in subjects seropositive at the last available follow-up time-point. -Post-challenge dose anti-HBsAg antibody concentrations \>= 10 mIU/mL in subjects seronegative at the last available follow-up time-point.
Time frame: One month after the hepatitis B vaccine challenge dose.
Population: Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects who had received the challenge dose of HBV vaccine and for whom data concerning immunogenicity measures were available at the post-HBV vaccine challenge dose time point.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) | Number of Subjects With an Anamnestic Response to a Challenge Dose of Hepatitis B Virus (HBV) Vaccine as Measured by Enzyme-Linked Immunosorbent Assay (ELISA). | 8 Subjects |
| Engerix(3-dose)+HBIg | Number of Subjects With an Anamnestic Response to a Challenge Dose of Hepatitis B Virus (HBV) Vaccine as Measured by Enzyme-Linked Immunosorbent Assay (ELISA). | 13 Subjects |
| Engerix(4-dose) | Number of Subjects With an Anamnestic Response to a Challenge Dose of Hepatitis B Virus (HBV) Vaccine as Measured by Enzyme-Linked Immunosorbent Assay (ELISA). | 6 Subjects |
| Engerix(3-dose) | Number of Subjects With an Anamnestic Response to a Challenge Dose of Hepatitis B Virus (HBV) Vaccine as Measured by Enzyme-Linked Immunosorbent Assay (ELISA). | 14 Subjects |
Secondary
Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by CLIA.
Concentrations given as GMC expressed as milli-international unit per millilitre (mIU/mL).
Time frame: One month after the hepatitis B vaccine challenge dose.
Population: Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects who had received the challenge dose of HBV vaccine and for whom data concerning immunogenicity measures were available at the post-HBV vaccine challenge dose time point.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by CLIA. | 1831.6 mIU/mL |
| Engerix(3-dose)+HBIg | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by CLIA. | 165.6 mIU/mL |
| Engerix(4-dose) | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by CLIA. | 1335.2 mIU/mL |
| Engerix(3-dose) | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by CLIA. | 454.1 mIU/mL |
Secondary
Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by ELISA.
Concentrations given as GMC expressed as milli-international unit per millilitre (mIU/mL).
Time frame: One month after the hepatitis B vaccine challenge dose.
Population: Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects who had received the challenge dose of HBV vaccine and for whom data concerning immunogenicity measures were available at the post-HBV vaccine challenge dose time point.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by ELISA. | 2852.1 mIU/mL |
| Engerix(3-dose)+HBIg | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by ELISA. | 163.8 mIU/mL |
| Engerix(4-dose) | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by ELISA. | 1420.2 mIU/mL |
| Engerix(3-dose) | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by ELISA. | 515.5 mIU/mL |
Secondary
Number of Subjects Experiencing Any, Grade 3 and Related to Vaccination Unsolicited Symptoms.
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 symptom is any event that prevented normal activities. Related symptom is an event that was considered by investigator as causally related to the study vaccination.
Time frame: During the 31-day follow-up period after the hepatitis B vaccine challenge dose.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) | Number of Subjects Experiencing Any, Grade 3 and Related to Vaccination Unsolicited Symptoms. | Subjects with any symptoms | 1 Subjects |
| Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) | Number of Subjects Experiencing Any, Grade 3 and Related to Vaccination Unsolicited Symptoms. | Subjects with related symptoms | 1 Subjects |
| Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) | Number of Subjects Experiencing Any, Grade 3 and Related to Vaccination Unsolicited Symptoms. | Subjects with grade 3 symptoms | 0 Subjects |
| Engerix(3-dose)+HBIg | Number of Subjects Experiencing Any, Grade 3 and Related to Vaccination Unsolicited Symptoms. | Subjects with any symptoms | 0 Subjects |
| Engerix(3-dose)+HBIg | Number of Subjects Experiencing Any, Grade 3 and Related to Vaccination Unsolicited Symptoms. | Subjects with related symptoms | 0 Subjects |
| Engerix(3-dose)+HBIg | Number of Subjects Experiencing Any, Grade 3 and Related to Vaccination Unsolicited Symptoms. | Subjects with grade 3 symptoms | 0 Subjects |
| Engerix(4-dose) | Number of Subjects Experiencing Any, Grade 3 and Related to Vaccination Unsolicited Symptoms. | Subjects with grade 3 symptoms | 0 Subjects |
| Engerix(4-dose) | Number of Subjects Experiencing Any, Grade 3 and Related to Vaccination Unsolicited Symptoms. | Subjects with any symptoms | 0 Subjects |
| Engerix(4-dose) | Number of Subjects Experiencing Any, Grade 3 and Related to Vaccination Unsolicited Symptoms. | Subjects with related symptoms | 0 Subjects |
| Engerix(3-dose) | Number of Subjects Experiencing Any, Grade 3 and Related to Vaccination Unsolicited Symptoms. | Subjects with any symptoms | 0 Subjects |
| Engerix(3-dose) | Number of Subjects Experiencing Any, Grade 3 and Related to Vaccination Unsolicited Symptoms. | Subjects with related symptoms | 0 Subjects |
| Engerix(3-dose) | Number of Subjects Experiencing Any, Grade 3 and Related to Vaccination Unsolicited Symptoms. | Subjects with grade 3 symptoms | 0 Subjects |
Secondary
Number of Subjects That Experienced Serious Adverse Events (SAEs)
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: During the entire study period after the challenge dose (1 month).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) | Number of Subjects That Experienced Serious Adverse Events (SAEs) | 0 Subjects |
| Engerix(3-dose)+HBIg | Number of Subjects That Experienced Serious Adverse Events (SAEs) | 0 Subjects |
| Engerix(4-dose) | Number of Subjects That Experienced Serious Adverse Events (SAEs) | 0 Subjects |
| Engerix(3-dose) | Number of Subjects That Experienced Serious Adverse Events (SAEs) | 0 Subjects |
Secondary
Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by CLIA.
Cut-off values assessed were as follows: ≥6.2 milli-international units/milliliter (mIU/mL), ≥10 mIU/mL, ≥100 mIU/mL
Time frame: One month after the hepatitis B vaccine challenge dose.
Population: Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects who had received the challenge dose of HBV vaccine and for whom data concerning immunogenicity measures were available at the post-HBV vaccine challenge dose time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by CLIA. | ≥ 6.2 mIU/mL | 7 Subjects |
| Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by CLIA. | ≥ 100 mIU/mL | 7 Subjects |
| Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by CLIA. | ≥ 10 mIU/mL | 7 Subjects |
| Engerix(3-dose)+HBIg | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by CLIA. | ≥ 6.2 mIU/mL | 12 Subjects |
| Engerix(3-dose)+HBIg | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by CLIA. | ≥ 100 mIU/mL | 7 Subjects |
| Engerix(3-dose)+HBIg | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by CLIA. | ≥ 10 mIU/mL | 12 Subjects |
| Engerix(4-dose) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by CLIA. | ≥ 10 mIU/mL | 6 Subjects |
| Engerix(4-dose) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by CLIA. | ≥ 6.2 mIU/mL | 6 Subjects |
| Engerix(4-dose) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by CLIA. | ≥ 100 mIU/mL | 6 Subjects |
| Engerix(3-dose) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by CLIA. | ≥ 6.2 mIU/mL | 15 Subjects |
| Engerix(3-dose) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by CLIA. | ≥ 100 mIU/mL | 11 Subjects |
| Engerix(3-dose) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by CLIA. | ≥ 10 mIU/mL | 15 Subjects |
Secondary
Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by ELISA.
Cut-off values assessed were as follows: ≥3.3 milli-international units/milliliter (mIU/mL), ≥10 mIU/mL, ≥100 mIU/mL
Time frame: One month after the hepatitis B vaccine challenge dose.
Population: Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects who had received the challenge dose of HBV vaccine and for whom data concerning immunogenicity measures were available at the post-HBV vaccine challenge dose time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by ELISA. | ≥ 3.3 mIU/mL | 8 Subjects |
| Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by ELISA. | ≥ 100 mIU/mL | 8 Subjects |
| Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by ELISA. | ≥ 10 mIU/mL | 8 Subjects |
| Engerix(3-dose)+HBIg | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by ELISA. | ≥ 3.3 mIU/mL | 14 Subjects |
| Engerix(3-dose)+HBIg | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by ELISA. | ≥ 100 mIU/mL | 8 Subjects |
| Engerix(3-dose)+HBIg | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by ELISA. | ≥ 10 mIU/mL | 13 Subjects |
| Engerix(4-dose) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by ELISA. | ≥ 10 mIU/mL | 6 Subjects |
| Engerix(4-dose) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by ELISA. | ≥ 3.3 mIU/mL | 6 Subjects |
| Engerix(4-dose) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by ELISA. | ≥ 100 mIU/mL | 6 Subjects |
| Engerix(3-dose) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by ELISA. | ≥ 3.3 mIU/mL | 15 Subjects |
| Engerix(3-dose) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by ELISA. | ≥ 100 mIU/mL | 12 Subjects |
| Engerix(3-dose) | Number of Subjects With Anti-Hepatitis B Surface (HBs) Antibody Concentrations Above Cut-off Values as Measured by ELISA. | ≥ 10 mIU/mL | 15 Subjects |